and negative, respectively. Regarding the buffy coat samples, iiRT-PCR detected EIAV nucleic acid in 31/56 AGID positive samples, while 108/109 AGID negative samples tested negative by iiRT-PCR. Total agreement was 84.24%. When whole blood samples were evaluated, a total of 16 iiRT-PCR positive and 15 iiRT-PCR negative out of 31 AGID positive samples were obtained. Additionally, EIAV nucleic acid was not detected in 25 AGID negative samples .Total agreement was 73.21% for this sample type. When evaluating the accuracy of EIAV iiRT-PCR and qPCR, 28/165 and 130/165 buffy coat samples tested positive and negative by both assays, respectively. Five iiRT-PCR positive samples were negative by qPCR and two qPCR positive samples were negative by iiRT-PCR. Thus, EIAV iiRT-PCR showed more than 95% agreement with qPCR results. It has been demonstrated that the absence of clinical signs is correlated with very low, frequently undetectable viremia. Therefore, EIAV iiRT-PCR appears to be a promising tool to identify infected horses including those experiencing low infectivity titers in blood. Furthermore, as initial EIAV replication rates are frequently high, recently infected equids pose a considerable transmission risk long before seroconversion. In our study, a horse was determined seronegative by AGID, but was identified as EIAV infected by iiRT-PCR. Thus, EIAV iiRT-PCR could be considered as an alternative diagnostic tool in the implementation of control strategies during an EIA outbreak in the low prevalence area of our country. . As part of test validation, the following five additional analyses were satisfactorily performed according to the OIE-recommended validation protocol: 1. the primary assay was calibrated with the OIE approved reference serum panel for EVA, 2. repeatability of the assay was evaluated within and between runs, 3. analytical specificity was evaluated using sera specific for selected equine viruses, 4. analytical sensitivity was evaluated with sera collected from horses vaccinated with the modified live virus vaccine against EVA (Arvac ® , Zoetis Animal Health), and 5. Duration of the positive cELISA antibody was evaluated following EVA vaccination. The analytical sensitivity of the new cELISA was comparable to the VN test in that it detected EAV-specific antibody as early as 6 days post-vaccination. The duration of EAV-specific antibody detection by cELISA was over six years post-vaccination. Based on the data obtained, significant correlation was demonstrated between the VN test and cELISA results (r 2 ¼0.79, P<0.0001). The cELISA was further improved using EAV purified by anion-exchange membrane chromatography (JVDI accepted). This enhanced cELISA was validated using diverse sera (n¼3255) at the Maxwell H. Gluck Equine Research Center. The relative sensitivity and specificity of this assay against a group of field sera (n¼1851) was 99.6% (95% CI 99.4-100.0) and 98.7% (95% CI 98.3, 99.6), respectively, compared to the VN test (manuscript submitted). This rapid, highly sensitive and specific cELISA compares very favorably to the VN test. It is USDA licensed and should facilitate screening of horses intended for international movement.

